SSRI CHINA news

Social Survey Research Information Co., Ltd. and M3, Inc. launched PatientsMap 2022CN (China 2022 version) on March 31, 2022.The data were obtained from a survey of member physicians on a portal site for medical professionals operated by Medlive.cn, an M3 Group company, with 11,000 physicians responding online.

In the survey, physicians were asked whether they have received sales rep visits from manufacturers. The survey was conducted from the end of last year to the beginning of March of this year, and analysis was performed based on an understanding that the results were obtained during a near normal period of time, when the spread of COVID-19 was relatively under control.

The results showed that major Western companies ranked at the top in many specialties, in particular, with AstraZeneca having the highest rate of sales rep visits in many specialties. While in oncology, three of the top five companies were local Chinese companies.